GENT Share Price

Open 55.44 Change Price %
High 55.93 1 Day -0.52 -0.94
Low 55.01 1 Week 0.00 0.00
Close 55.04 1 Month 0.00 0.00
Volume 14059 1 Year 0.00 0.00
52 Week High 2.89
52 Week Low 0.70
GENT Important Levels
Resistance 2 55.89
Resistance 1 55.54
Pivot 55.33
Support 1 54.54
Support 2 54.19
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
RITT 0.04 33.33%
SCHS 0.04 33.33%
RPRX 0.56 27.27%
ATRM 1.73 27.21%
BSDM 0.62 26.53%
TISA 1.63 26.36%
SNTA 0.34 25.93%
OTT 2.39 25.13%
DGLY 2.65 20.45%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
DRRX 0.78 -60.41%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Gentium SpA (NASDAQ: GENT)

GENT Technical Analysis 2.5
As on 7th Mar 2014 GENT Share Price closed @ 55.04 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 29.73 & Strong Sell for SHORT-TERM with Stoploss of 56.82 we also expect STOCK to react on Following IMPORTANT LEVELS.
GENT Target for October
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
GENT Other Details
Segment EQ
Market Capital 168203280.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
GENT Address
GENT
N/A
GENT Latest News
Interactive Technical Analysis Chart Gentium SpA ( GENT NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Gentium SpA
GENT Business Profile
GENTIUM S.p.A is a biopharmaceutical company focused on the development and manufacture of its product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded deoxyribonucleic acid (DNA) extracted from pig intestines. The Company�s development of defibrotide has been focused on the treatment and prevention of a disease called hepatic veno-occlusive disease ( VOD), a condition that occurs when veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation, that are administered prior to stem cell transplantation. In February 2014, Jazz Pharmaceuticals PLC acquired the 98% interest in Gentium SpA (Gentium).